- Home
- ATEX vs DNA Comparison
ATEX vs DNA Comparison
Compare ATEX & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- DNA
- Stock Information
- Founded
- ATEX 1997
- DNA 2008
- Country
- ATEX United States
- DNA United States
- Employees
- ATEX N/A
- DNA N/A
- Industry
- ATEX Telecommunications Equipment
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATEX Telecommunications
- DNA Health Care
- Exchange
- ATEX Nasdaq
- DNA Nasdaq
- Market Cap
- ATEX 528.1M
- DNA 466.4M
- IPO Year
- ATEX N/A
- DNA N/A
- Fundamental
- Price
- ATEX $26.59
- DNA $6.94
- Analyst Decision
- ATEX Buy
- DNA Sell
- Analyst Count
- ATEX 2
- DNA 3
- Target Price
- ATEX $64.00
- DNA $9.67
- AVG Volume (30 Days)
- ATEX 109.9K
- DNA 1.1M
- Earning Date
- ATEX 06-25-2025
- DNA 05-06-2025
- Dividend Yield
- ATEX N/A
- DNA N/A
- EPS Growth
- ATEX N/A
- DNA N/A
- EPS
- ATEX N/A
- DNA N/A
- Revenue
- ATEX $5,902,000.00
- DNA $237,417,000.00
- Revenue This Year
- ATEX $49.39
- DNA N/A
- Revenue Next Year
- ATEX $2.84
- DNA $15.26
- P/E Ratio
- ATEX N/A
- DNA N/A
- Revenue Growth
- ATEX 66.77
- DNA 13.76
- 52 Week Low
- ATEX $26.50
- DNA $5.00
- 52 Week High
- ATEX $42.91
- DNA $23.29
- Technical
- Relative Strength Index (RSI)
- ATEX 30.24
- DNA 44.32
- Support Level
- ATEX $27.02
- DNA $6.65
- Resistance Level
- ATEX $29.14
- DNA $7.62
- Average True Range (ATR)
- ATEX 1.08
- DNA 0.51
- MACD
- ATEX 0.02
- DNA -0.08
- Stochastic Oscillator
- ATEX 2.71
- DNA 16.34
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.